Licensing deal
Gene therapy specialist Amsterdam Molecular Therapeutics, a spin-out from the Amsterdam Academic Medical Centre, The Netherlands, has obtained a licence from US biotech Amgen to use its GDNF (glial cell line–derived neurotrophic factor) gene in the development of a treatment for Parkinson’s disease.
The Dutch company says the combination of this gene with its proprietary adeno-associated viral delivery system could potentially lead to the development of a long-term treatment for the disease.
GDNF encodes for a protein that is necessary for the development and survival of nerve cells. In animal studies the gene has been shown to protect and enhance the function of dopamine-producing cells and Amsterdam Molecular Therapeutics believes that its gene-delivery platform may overcome problems in delivering GDNF to the brain.
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
